Kilitch Drugs (India) (BOM:524500) ROCE % : 10.61% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Kilitch Drugs (India) ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kilitch Drugs (India)'s annualized ROCE % for the quarter that ended in Dec. 2023 was 10.61%.

Kilitch Drugs (India) ROCE % Historical Data

The historical data trend for Kilitch Drugs (India)'s ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kilitch Drugs (India) ROCE % Chart

Kilitch Drugs (India) Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

7.59

1.90

4.69

8.00

11.63

Kilitch Drugs (India) Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															10.31	16.78	15.80	19.89	10.61

Kilitch Drugs (India) ROCE % Calculation

Kilitch Drugs (India)'s annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	169.332	/	( ( (2098.482 - 692.792)	+	(2195.213 - 688.731) )	/ 2 )
	=	169.332	/	( (1405.69	+	1506.482)	/ 2 )
	=	169.332	/	1456.086
	=	11.63 %

Kilitch Drugs (India)'s ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	176.848	/	( ( (2370.048 - 702.609)	+	(0 - 0) )	/ 1 )
	=	176.848	/	( ( 1667.439	+	0 )	/ 1 )
	=	176.848	/	1667.439
	=	10.61 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Kilitch Drugs (India) (BOM:524500) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kilitch Drugs (India) ROCE % Related Terms

Thank you for viewing the detailed overview of Kilitch Drugs (India)'s ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kilitch Drugs (India) (BOM:524500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kilitch Drugs (India) Ltd (BOM:524500) » Definitions » ROCE %

Traded in Other Exchanges

KILITCH:India

Address

Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088

Website

https://www.kilitch.com

Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in the manufacture and sales of pharmaceutical products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, HPURE, and others. The company has one reportable segment, which is the development and operations of the Pharmaceutical business. The company has a geographical presence in African countries and several Asian countries.

Kilitch Drugs (India) (BOM:524500) Headlines

No Headlines